Mazdutide Phase 3 trial (NCT05607680)
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 610
- actual
- Start
- 14 Nov 2022 (actual)
- Primary completion
- 21 Aug 2023 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo | Placebo comparator | Drug: Placebo | Placebo,SC,once a week for 48 weeks |
| IBI362 4 mg | Experimental | Drug: IBI362 | 2 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 44 weeks |
| IBI362 6 mg | Experimental | Drug: IBI362 | 2 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 4 weeks 6 mg,SC,once a week for 40 weeks |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 32 |
| Percentage of Participants who Achieve ≥5% Body Weight Reduction | Week 32 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percentage of Participants who Achieve ≥10%Body Weight Reduction | Week 32,Week 48 |
| Percentage of Participants who Achieve ≥15% Body Weight Reduction | Week 32,Week 48 |
| Change from Baseline in Waist Circumference | Baseline, Week 32,Week 48 |
| Percent Change from Baseline in Body Weight | Baseline, Week 48 |
| Percentage of Participants who Achieve ≥5% Body Weight Reduction | Week 48 |
| Percentage of Participants who Achieve ≥20% Body Weight Reduction | Week 32, Week 48 |
| Change from Baseline in Neck Circumference | Baseline, Week 32, Week 48 |
| Change from Baseline in Hip Circumference | Baseline, Week 32, Week 48 |
| Change from Baseline in Body Weight | Baseline, Week 32, Week 48 |
| Percent Change from Baseline in Body Weight | Baseline, Week 60 |
| Change from Baseline in Body Mass Index (BMI) | Baseline, Week 32, Week 48 |
| Percentage of Participants with BMI < 24 kg/m2 | Week 32, Week 48 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
GLORY-1 results as published for 4 mg and 6 mg mazdutide
Chinese adults with a BMI of at least 28, or 24 to under 28 with a weight-related condition, were randomised 1:1:1 to mazdutide 4 mg, 6 mg or placebo for 48 weeks.[2]
At week 32 weight changed by -10.09% on 4 mg, -12.55% on 6 mg and +0.45% on placebo, and 73.9%, 82.0% and 10.5% respectively lost at least 5%.[2]
At week 48 the weight changes were -11.00%, -14.01% and +0.30%, with 35.7%, 49.5% and 2.0% losing at least 15%.[2]
Adverse events led to discontinuation in 1.5% on 4 mg, 0.5% on 6 mg and 1.0% on placebo.[2]
Sources
- 1A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026
Found an error? Report a correction.